Hepatitis C accounted for a 0.9% share of the global clinical trials within the Infectious Disease therapy area in 2021, registering a decrease of 9.4% when compared with the last ten-year average of 10.3% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Hepatitis C
Industry sponsored trials held a 42.9% share of all the clinical trials for Hepatitis C indication in 2021, registering a decrease of 5.4% when compared with the ten-year average of 48.3%. Non-industry sponsored trials accounted for a 57.1% share in 2021, registering an increase of 5.4% over the ten-year average of 51.7%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Hepatitis C trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNorth America was the top region for industry sponsored Hepatitis C trials, accounting for a 53.3% share in 2021, when compared with the five-year average of 18.3% and ten-year average of 37.9%.
Asia-Pacific was at the second position with a 26.7% share in 2021, over the five-year average of 66.0% and ten-year average of 51.0%, followed by Europe with a 26.7% share in 2021, as against five-year and ten-year averages of 28.6% and 38.6% respectively.
Middle East and Africa stood fourth with a 6.7% share in 2021, compared with the five-year average of 6.3% and ten-year average of 7.4%, followed by South and Central America with a 0.0% share in 2021, over five-year and ten-year averages of 1.4% and 3.6% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Canada was the top country for industry sponsored Hepatitis C trials, accounting for a 40.0% share in 2021, as against the five-year average of 7.0% and ten-year average of 12.5%.
The US held a 20.0% share in 2021, over the five-year average of 14.5% and ten-year average of 34.4%, followed by China with a 20.0% share in 2021, compared with the five-year and ten-year averages of 36.7% and 20.6% respectively.
Australia held a 6.7% share in 2021, as against the five-year average of 7.3% and ten-year average of 11.6%.
Austria held a 6.7% share in 2021, over the five-year and ten-year averages of 0.4% and 3.8% respectively.
Top regions of non-industry sponsored Hepatitis C trials
Asia-Pacific was the top region for non-industry sponsored Hepatitis C trials, accounting for a 50.0% share in 2021 when compared with the five-year average of 42.2% and ten-year average of 42.8%.
Europe was at the second position with a 20.0% share in 2021, over the five-year and ten-year averages of 14.0% and 20.6% respectively, followed by North America with a 20.0% share in 2021, as against the five-year average of 25.5% and ten-year average of 23.3%.
Middle East and Africa stood at the fourth position with a 10.0% share in 2021, compared with the five-year average of 20.3% and ten-year average of 13.5%, followed by South and Central America with a 5.0% share in 2021, over the five-year and ten-year averages of 1.2% and 1.6% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for non-industry sponsored Hepatitis C trials, accounting for a 20.0% share in 2021, as against the five-year average of 24.0% and ten-year average of 21.3%.
China held a 15.0% share in 2021, over the five-year average of 10.8% and ten-year average of 8.4%, followed by Pakistan with a 10.0% share, compared with the five-year and ten-year averages of 1.0% and 1.1% respectively.
Taiwan held a 10.0% share in 2021, as against the five-year average of 2.3% and ten-year average of 2.2%.
Spain held a 5.0% share in 2021, over the five-year average of 2.2% and ten-year average of 3.0%.
Phase I trials lead industry sponsored clinical trials for Hepatitis C in 2021
Phase I trials held an 86.7% share of industry sponsored clinical trials for Hepatitis C in 2021, over the five-year average of 43.1% and ten-year average of 41.4%.
Phase II trials held a 6.7% share in 2021, as against the five-year average of 19.8% and ten-year average of 22.8%. Phase III trials held a 6.7% share in 2021, compared with the five-year and ten-year averages of 15.4% and 20.5% respectively.
Phase IV trials held a 0.0% share in 2021, over the five-year average of 21.8% and ten-year average of 15.3%.
Phase IV trials lead non-industry sponsored clinical trials for Hepatitis C in 2021
Phase IV trials held a 60.0% share of non-industry sponsored clinical trials for Hepatitis C in 2021, over the five-year average of 49.4% and ten-year average of 42.7%.
Phase I trials held a 15.0% share in 2021, as against the five-year average of 9.1% and ten-year average of 8.3%. Phase II trials held a 15.0% share, compared with the five-year and ten-year averages of 30.0% and 37.2% respectively.
Phase III trials held a 10.0% share in 2021, over the five-year average of 11.4% and ten-year average of 11.7%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
